Skip to main content
ARTV
NASDAQ Life Sciences

RA Capital, a 10% owner and director, makes $4.6M open market purchase of Artiva Biotherapeutics stock.

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$8.9
Mkt Cap
$220.226M
52W Low
$1.47
52W High
$14.53
52W Position info
505% above low
Off High info
39% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

ARTV has more than doubled off its 52-week low of $1.47.

Summary

RA Capital, a major institutional investor and director, further increased its stake in Artiva Biotherapeutics with a $4.6 million open market purchase, signaling strong confidence.


Key Events · Ownership and Investor Activity · ARTV

  • Significant Insider Purchase

    RA Capital, a 10% owner and director, acquired $4,599,903 worth of common stock through open market purchases between June 12 and June 16, 2026.

  • Material Stake Increase

    The purchase represents over 2% of Artiva Biotherapeutics' market capitalization, reinforcing RA Capital's position as a key investor.

  • Continued Accumulation

    This transaction extends a pattern of substantial accumulation by RA Capital and other major shareholders, following recent positive clinical data and a $300 million offering.


Analysis · ARTV · Life Sciences

This $4.6 million open market purchase by RA Capital, a major institutional investor with board representation, represents over 2% of Artiva Biotherapeutics' market capitalization. It signifies strong conviction in the company's future, especially as it follows recent positive clinical data and a significant capital raise. This continued accumulation by a key insider group reinforces investor confidence.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARTV was trading at $8.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $220.2M. The 52-week trading range was $1.47 to $14.53. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARTV - Latest Insights

ARTV
Nov 09, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.22
Real-time Price: $3.84 info
Change: -$0.380 (-9%) info
Market Cap: $190.315M info
ARTV
Oct 27, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.09
Real-time Price: $3.84 info
Change: -$0.250 (-6%) info
Market Cap: $190.315M info
ARTV
Oct 27, 2026, 7:30 AM EDT
Source: Wiseek News
Importance Score:
10
Price at Filing: $6.30
Real-time Price: $3.84 info
Change: -$2.46 (-39%) info
Market Cap: $190.315M info
ARTV
Oct 01, 2026, 7:30 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $7.25
Real-time Price: $3.84 info
Change: -$3.41 (-47%) info
Market Cap: $190.315M info
ARTV
Aug 06, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.58
Real-time Price: $3.84 info
Change: -$7.74 (-67%) info
Market Cap: $190.315M info